Skip to main content
SpringerLink
Log in

INGN 201

Ad-p53, Ad5CMV-p53, Adenoviral p53, p53 Gene Therapy — Introgen, RPR/INGN 201

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Introgen Therapeutics Inc. Introgen Therapeutics Awarded Additional ADVEXIN Patent. Media Release: 20 Jun 2005. Available from URL: http://www.introgen.com

    Google Scholar 

  2. Introgen Therapeutics Inc. Introgen’s ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances. Media Release: 17 Oct 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  3. Introgen Therapeutics Inc. Introgen Announces New Clinical Data for ADVEXIN and Submits Request to Food and Drug Administration for Initiation of Accelerated Approval Biologics License Application. Media Release: 23 Dec 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  4. Introgen Therapeutics Inc. Southwest Oncology Group Initiates Phase 2 Clinical Trial Using Introgen’s Advexin(R) Cancer Therapy. Media Release: 21 Apr 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  5. Introgen Therapeutics Inc, Southwest Oncology Group. Introgen’s Advexin Therapy To Be Combined With Surgery in Phase II Trial; Introgen and Southwest Oncology Group Enter Agreement for Clinical Testing. Media Release: 24 Nov 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  6. Introgen Therapeutics Inc. Introgen Receives FDA Fast Track Designation for Advexin(R). Media Release: 17 Sep 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  7. Introgen Therapeutics Inc. Introgen’s ADVEXIN(R) Receives Orphan Drug Designation From the FDA. Media Release: 20 Feb 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  8. Introgen Therapeutics. Introgen Therapeutics and the National Cancer Institute Begin Clinical Trial For Advexin as Mouthwash for Oral Premalignancies. Media Release: 19 Nov 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  9. Gendux AB, Introgen Therapeutics Inc. Introgen Therapeutics and Gendux AB Announce Orphan Designation for ADVEXIN Therapy in the EU. Media Release: 7 Sep 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  10. Introgen Therapeutics Inc. Gendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN. Media Release: 9 May 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  11. Introgen Therapeutics Inc. Introgen’s ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome. Media Release: 8 May 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  12. Introgen Therapeutics Inc. Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes. Media Release: 3 Nov 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  13. Introgen Therapeutics Inc. Introgen Awarded Patent for Gene-Based Therapies Combined With Conventional Therapies. Media Release: 14 Feb 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  14. Introgen Therapeutics Inc. Introgen Therapeutics Adds 15th Adenoviral p53 Related Patent to Portfolio. Media Release: 20 Oct 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  15. Introgen Therapeutics Inc. Patent Added to Introgen’s Portfolio Establishes Control of Pharmaceutical Adenoviral p53 Products. Media Release: 15 Jun 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  16. Introgen Therapeutics Inc, Board of Regents of the University of Texas System. Important Patent Issued for Introgen’s ADVEXIN(R) Cancer Therapeutic; Claims Focus on DNA Core of Drug. Media Release: 5 Feb 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  17. Introgen Therapeutics Inc. Introgen Announces Additional Broad Patent in China for p53 Combination Therapies. Media Release: 8 Aug 2005. Available from URL: http://www.introgen.com

    Google Scholar 

  18. Introgen Therapeutics Inc. Introgen p53 Therapy Patent Is Affirmed in Europe Following Opposition By Schering-Plough. Media Release: 23 Feb 2006. Available from URL: http://www.introgen.com

    Google Scholar 

  19. Introgen Therapeutics Inc. Clinical Safety and Efficacy Data of Introgen’s Late-Stage Cancer Candidate, ADVEXIN(R), Featured at Scientific Meeting. Media Release: 3 Jun 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  20. Introgen Therapeutics Inc. Introgen Therapeutics’ ADVEXIN Gene Therapeutic Experience Highlighted At International p53 Meeting. Media Release: 25 Jun 2002. Available from URL: http://www.introgen.com

    Google Scholar 

  21. Rhone-Poulenc Rorer. Phase II p53 gene therapy clinical trials show evidence of tumor growth control in head and neck cancer patients. Media Release: [3 pages], 18 May 1999. Available from http://www.rp-rorer.com

    Google Scholar 

  22. Yver A, Dreiling LK, Mohanty S, et al. Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in phase I and II studies world-wide. 36th Annual Meeting of the American Society of Clinical Oncology 19: 460 (plus poster), 20 May 2000

    Google Scholar 

  23. Hao D, Rowinsky EK, Smetzer LA, et al. A phase I and pharmacokinetic study of intravenous p53 gene therapy with RPR/INGN-201 in patients with advanced cancer. 37th Annual Meeting of the American Society of Clinical Oncology 20: 262, Part 1, 12 May 2001

    Google Scholar 

  24. Nemunaitis J, Goodwin WJ, Bier-Laning C, et al. Intratumoral adenoviral-mediated p53 gene therapy is associated with a survival advantage in recurrent squamous cell cancer of the head and neck based on a dose response model using phase 2 data. 93rd Annual Meeting of the American Association for Cancer Research — Supplement: 83 (plus poster), 6 Apr 2002

  25. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delviery of adenoviral p53 (INGN 201) and radiation therapy. Clinical Cancer Research 9: 93–101, Jan 2003

    PubMed  CAS  Google Scholar 

  26. Introgen Therapeutics Inc. Introgen’s adenoviral vector demon-strates safety in phase II study; biosafety data presented at American Society of Gene Therapy Meeting. Media Release: [2 pages], 1 Jun 2001. Available from URL: http://www.introgen.com

    Google Scholar 

  27. Introgen Therapeutics Inc. Introgen presents new safety information for INGN 201 in cancer. Media Release: [2 pages], 17 Dec 2001. Available from URL: http://www.introgen.com

    Google Scholar 

  28. Introgen Therapeutics Inc. Introgen’s ADVEXIN Cancer Therapy in Combination With Chemotherapy Effective Against Head and Neck Cancer Cells. Media Release: 8 Nov 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  29. Bacchetti S, Graham FL. Inhibition of cell proliferation by an adenovirus vector expressing the human wild type-p53 protein. International Journal of Oncology 3: 781–788, Nov 1993

    PubMed  CAS  Google Scholar 

  30. Clayman GL, El-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Research 55: 1–6, 1 Jan 1995

    PubMed  CAS  Google Scholar 

  31. Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expres sing mutant p53 protein. Cancer Gene Therapy 3: 121–130, Mar–Apr 1996

    PubMed  CAS  Google Scholar 

  32. Yoo GH, Washington J, Oliver J, et al. The effects of exogenous p53 overexpression on HPV-immortalized and carcinogen transformed oral keratinocytes. Cancer 94: 159–166, 1 Jan 2002

    Article  PubMed  CAS  Google Scholar 

  33. Nikitina EY, Chada S, Muro-Cacho C, et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Therapy 9: 345–352, Mar 2002

    Article  PubMed  CAS  Google Scholar 

  34. Pagliaro LC, Keyhani A, Liu B, et al. Gene therapy in bladder cancer: phase I results with Ad5CMV-p53 (RPR/INGN 201). 37th Annual Meeting of the American Society of Clinical Oncology 20: 200 (plus poster), Part 1, 12 May 2001

    Google Scholar 

  35. Introgen Therapeutics Inc. Addition of ADVEXIN(R) to Chemotherapy Shows Promise in Treating Locally Advanced Breast Cancer. Media Release: 9 Dec 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  36. Introgen Therapeutics Inc. Introgen’s ADVEXIN(R) Combined With Aventis’ Taxotere(R) and Pharmacia’s Adriamycin(R) in Development for Breast Cancer. Media Release: 13 Jan 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  37. Introgen Therapeutics Inc. Phase 2 Breast Cancer Study Shows Clinical Responses in 90 Percent of Patients Treated With Introgen’s Advexin Therapy. Media Release: 3 Jun 2003. Available from URL: http://www.introgen.com

    Google Scholar 

  38. Cristofanilli M, Khrisnamurthy S, Guerra L, et al. Ad5CMV-p53 combined with docetaxel and doxorubicin as induction chemotherapy for patients with locally advanced breast cancer: preliminary report of safety and efficacy. 39th Annual Meeting of the American Society of Clinical Oncology: 241, 31 May 2003

    Google Scholar 

  39. Introgen Therapeutics Inc. Introgen Presents Advexin(R) Clinical Data for Recurrent Head and Neck Cancer in Late Breaking Session at AACR. Media Release: 30 Mar 2004. Available from URL: http://www.introgen.com

    Google Scholar 

  40. Results of first gene therapy study to demonstrate tumor regression and positive safety profile in head and neck cancer pesented at ASCO. PR Newswire [online]: [3 pages], 19 May 1997. Available from URL: http://www.newspage.com

  41. Clayman GL, El-Naggar AK, Merritt J. Adenovirus-mediated p53 gene transfer in a phase I trial of patients with advanced recurrent head and neck squamous carcinoma. 33rd Annual Meeting of the American Society of Clinical Oncology: 383, 17 May 1997

    Google Scholar 

  42. Merritt JA, Clayman G, Schwisher S. Clinical gene therapy strategies: phase I/II results with adenoviral P53 (INGN 201) gene transfer in advanced head and neck and non small cell lung cancers. 3rd European Conference on Gene Therapy of Cancer: 175, 11 Sep 1997

    Google Scholar 

  43. Bier-Laning CM, VanEcho D, Yver A. A phase II multi-center study of AD5CMV-P53 administered intratumorally to patients with recurrent head and neck cancer. 35th Annual Meeting of the American Society of Clinical Oncology 18: 444, 15 May 1999

    Google Scholar 

  44. Gene therapy experiment works in lung cancer-study. Media Release: [2 pages], 6 May 1999

  45. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. Journal of Clinical Oncology 18: 609–622, Feb 2000

    PubMed  CAS  Google Scholar 

  46. Introgen Therapeutics Inc. Lung Cancer Patient Reaches Five Year Survival Mark After Treatment With Introgen’s ADVEXIN(R) Gene Drug Therapy. Media Release: 2 Jul 2002. Available from URL: http://www.introgen.com

    Google Scholar 

  47. Introgen Therapeutics Inc. Introgen Therapeutics reports progress in gene therapy studies at annual ASCO meeting — gene therapy can be combined with radiation therapy and may improve local. Media Release: [4 pages], 22 May 2000. Available from URL: http://www.introgen.com

    Google Scholar 

  48. Swisher S, Roth JA, Komaki R, et al. A phase II trial of adenoviral mediated P53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer. 36th Annual Meeting of the American Society of Clinical Oncology 19: 461 (plus poster), 20 May 2000

    Google Scholar 

  49. Swisher S, Roth J, Komaki R, et al. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 and radiation therapy in patients with non-small cell lung cancer. 37th Annual Meeting of the American Society of Clinical Oncology 20: 257 (plus poster), Part 1, 12 May 2001

    Google Scholar 

  50. Introgen Therapeutics Inc. Introgen’s ADVEXIN(R) Combined With Radiation Well Tolerated and Shows Tumor Regression in Phase 2 Lung Cancer Study. Media Release: 14 Jan 2003. Available from URL: http://www.introgen.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

INGN 201. Drugs R D 8, 176–187 (2007). https://doi.org/10.2165/00126839-200708030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708030-00005

Keywords

Search

Navigation